Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin in Treatment-Resistant Depression
NCT05029466Phase 2Completed
- Sponsor
- Brain and Cognition Discovery Foundation
- Start
- Nov 2021
- Primary completion
- Jul 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of psilocybin in treatment-resistant depression (TRD), sponsored by Brain and Cognition Discovery Foundation. Started Nov 2021; status: completed.
02
Drugs
psilocybin
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT05029466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05029466.